SET binding protein 1 is a protein that in humans is encoded by the SETBP1 gene.[5]
Gene
The gene is located on Chromosome 18, specifically on the long (q) arm of the chromosome at position 12.3. This is also written as 18q12.3.
Function
The SETBP1 gene provides instructions for making a protein known as the SET binding protein 1, which is widely distributed throughout somatic cells. The protein is known to bind to another protein called SET. SETBP1 is a DNA-binding protein that forms part of a group of proteins that act together on histone methylation to make chromatin more accessible and regulate gene expression.[6] There is still more to learn about the overall function of the SETBP1 protein
and the effect of SET binding.
Loss-of-function mutations in the SETBP1 gene are associated with a SETBP1-related developmental delay called SETBP1 disorder which causes a spectrum of symptoms including absent speech/expressive language delays, mild-severe intellectual disability, autistic-traits/autism, developmental delays, ADHD, and seizures.[8][9]
SETBP1 is an oncogene; specific somatic mutations of this gene were discovered in patients affected by atypical Chronic Myeloid Leukemia (aCML) and related diseases. These mutations, which are identical to the ones present in SGS as germ line mutations, impair the degradation of SETBP1 and therefore cause increased cellular levels of the protein.[10]
^Filges I, Shimojima K, Okamoto N, Röthlisberger B, Weber P, Huber AR, et al. (Feb 2011). "Reduced expression by SETBP1 haploinsufficiency causes developmental and expressive language delay indicating a phenotype distinct from Schinzel-Giedion syndrome". Journal of Medical Genetics. 48 (2): 117–22. doi:10.1136/jmg.2010.084582. PMID21037274. S2CID38823269.
Minakuchi M, Kakazu N, Gorrin-Rivas MJ, Abe T, Copeland TD, Ueda K, et al. (Mar 2001). "Identification and characterization of SEB, a novel protein that binds to the acute undifferentiated leukemia-associated protein SET". European Journal of Biochemistry. 268 (5): 1340–51. doi:10.1046/j.1432-1327.2001.02000.x. hdl:2433/150179. PMID11231286.
Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U, et al. (Apr 2006). "Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1". Nature Medicine. 12 (4): 401–9. doi:10.1038/nm1393. PMID16582916. S2CID7601162.
Filges I, Shimojima K, Okamoto N, Röthlisberger B, Weber P, Huber AR, et al. (Feb 2011). "Reduced expression by SETBP1 haploinsufficiency causes developmental and expressive language delay indicating a phenotype distinct from Schinzel-Giedion syndrome". Journal of Medical Genetics. 48 (2): 117–22. doi:10.1136/jmg.2010.084582. PMID21037274. S2CID38823269.
Marseglia G, Scordo MR, Pescucci C, Nannetti G, Biagini E, Scandurra V, et al. (Mar 2012). "372 kb microdeletion in 18q12.3 causing SETBP1 haploinsufficiency associated with mild mental retardation and expressive speech impairment". European Journal of Medical Genetics. 55 (3): 216–21. doi:10.1016/j.ejmg.2012.01.005. PMID22333924.
Ganesan AK, Kho Y, Kim SC, Chen Y, Zhao Y, White MA (Jun 2007). "Broad spectrum identification of SUMO substrates in melanoma cells". Proteomics. 7 (13): 2216–21. doi:10.1002/pmic.200600971. PMID17549794. S2CID46295254.
